4. References

1. Getahun H, Matteelli A, Chaisson RE, Raviglione M. Latent Mycobacterium tuberculosis Infection. N Engl J Med. 2015 May 28;372(22):2127–35.

2. Dodd PJ, Gardiner E, Coghlan R, Seddon JA. Burden of childhood tuberculosis in 22 high-burden countries: a mathematical modelling study. Lancet Glob Health. 2014 Aug;2(8):e453–9.

3. Houben RMGJ, Dodd PJ. The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling. PLOS Medicine. 2016 Oct 25;13(10):e1002152.

4. Comstock GW, Livesay VT, Woolpert SF. The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol. 1974 Feb;99(2):131–8.

5. Vynnycky E. Lifetime Risks, Incubation Period, and Serial Interval of Tuberculosis. Am J Epidemiol. 2000 Aug 1;152(3):247–63.

6. United Nations General Assembly. Resolution A/RES/73.3. Political declaration of the high-level meeting of the General Assembly on the fight against tuberculosis. In 2018. Available from: http://www.un.org/en/ga/ search/view_doc.asp?symbol=A/RES/73/3

7. Uplekar M, Weil D, Lönnroth K, Jaramillo E, Lienhardt C, Dias HM, et al. WHO’s new end TB strategy. Lancet. 2015 May 2;385(9979):1799–801.

8. Implementing the End TB Strategy: the essentials (WHO/HTM/TB/2015.31). Geneva, World Health Organization. 2015. Available from: http://www.who.int/tb/publications/2015/end_tb_essential.pdf

9. Lönnroth K, Migliori GB, Abubakar I, D’Ambrosio L, de Vries G, Diel R, et al. Towards tuberculosis elimination: an action framework for low-incidence countries. Eur Respir J. 2015 Apr;45(4):928–52.

10. Global tuberculosis report 2019 (WHO/CDS/TB/2019.15). Geneva, World Health Organization; 2019. Available from: https://apps.who.int/iris/bitstream/handle/10665/329368/9789241565714-eng.pdf

11. Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. Geneva, World Health Organization. 2011. Available from: https:// apps.who.int/iris/bitstream/handle/10665/44472/9789241500708_eng.pdf

12. Guidance for national tuberculosis programmes on the management of tuberculosis in children. 2nd ed. (WHO/TB/2014.03). Geneva, World Health Organization; 2014. Available from: http://apps.who.int/iris/ bitstream/10665/112360/1/9789241548748_eng.pdf

13. Guidelines on the management of latent tuberculosis infection (WHO/HTM/TB/2015.01). Geneva, World Health Organization. 2015. Available from: http://apps.who.int/iris/bitstream/10665/136471/1/9789241548908_ eng.pdf

14. Getahun H, Matteelli A, Abubakar I, Aziz MA, Baddeley A, Barreira D, et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J. 2015 Dec;46(6):1563–76.

15. Recommendations for investigating contacts of persons with infectious tuberculosis in low- and middleincome countries (WHO/HTM/TB/2012.9). Geneva, World Health Organization; 2012. Available from: http:// www.who.int/tb/publications/2012/contact_investigation2012/en/

16. Latent TB Infection : Updated and consolidated guidelines for programmatic management (WHO/CDS/TB/2018.4). Geneva, World Health Organization. 2018. Available from: http://apps.who.int/iris/bitstream/handle/10665/260233/9789241550239-eng.pdf

17. Ford N, Matteelli A, Shubber Z, Hermans S, Meintjes G, Grinsztejn B, et al. TB as a cause of hospitalization and in-hospital mortality among people living with HIV worldwide: a systematic review and meta-analysis. Journal of the International AIDS Society. 2016 Jan;19(1):20714.

18. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane HIV/AIDS Group, editor. Cochrane Database of Systematic Reviews. 2010 Jan 20 [cited 2019 Jul 29]; Available from: http://doi.wiley.com/10.1002/14651858.CD000171.pub3

19. Chaisson L, Saraceni V, Cohn S, Cavalcante S, Chaisson RE, Golub J, et al. CD4 count-based guidelines for tuberculin skin testing and tuberculosis preventive therapy in people living with HIV. In Mexico; 2019 [cited 2019 Oct 4]. Available from: http://programme.ias2019.org/Abstract/Abstract/3724

20. Rangaka MX, Wilkinson RJ, Boulle A, Glynn JR, Fielding K, van Cutsem G, et al. Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial. The Lancet. 2014 Aug;384(9944):682–90.

21. The TEMPRANO ANRS 12136 Study Group. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. N Engl J Med. 2015 Aug 27;373(9):808–22.

22. Badje A, Moh R, Gabillard D, Guéhi C, Kabran M, Ntakpé J-B, et al. Effect of isoniazid preventive therapy on risk of death in west African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the Temprano ANRS 12136 trial. Lancet Glob Health. 2017 Nov;5(11):e1080–9.

23. Bruins WS, van Leth F. Effect of secondary preventive therapy on recurrence of tuberculosis in HIV-infected individuals: a systematic review. Infect Dis. 2017 Mar 4;49(3):161–9.

24. Evaluation of the Effect of 3HP vs Periodic 3HP vs 6H in HIV-Positive Individuals (WHIP3TB). 2016. Available from: https://clinicaltrials.gov/ct2/show/NCT02980016

25. Recommendation on 36 months isoniazid preventive therapy to adults and adolescents living with HIV in resource-constrained and high TB- and HIV-prevalence settings – 2015 update (WHO/HTM/TB/2015.15 / WHO/HIV/2015.13). Geneva, World Health Organization. 2015. Available from: https://apps.who.int/iris/bitstream/handle/10665/174052/9789241508872_eng.pdf

26. WHO Guidelines on tuberculosis infection prevention and control, 2019 update (WHO/CDS/TB/2019.1). Geneva, World Health Organization. 2019. Available from: https://apps.who.int/iris/bitstream/handle/10665/311259/9789241550512-eng.pdf

27. Getahun H, Sculier D, Sismanidis C, Grzemska M, Raviglione M. Prevention, Diagnosis, and Treatment of Tuberculosis in Children and Mothers: Evidence for Action for Maternal, Neonatal, and Child Health Services. J Infect Dis. 2012 May 15;205(suppl 2):S216–27.

28. US FDA. Isoniazid Tablets, USP. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/008678s028lbl.pdf

29. US FDA. RIFADIN® (rifampin capsules USP) and RIFADIN ® IV (rifampin for injection USP). Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/050420s073,050627s012lbl.pdf

30. Zar HJ, Cotton MF, Strauss S, Karpakis J, Hussey G, Schaaf HS, et al. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. BMJ. 2007 Jan 20;334(7585):136.

31. Madhi SA, Nachman S, Violari A, Kim S, Cotton MF, Bobat R, et al. Primary Isoniazid Prophylaxis against Tuberculosis in HIV-Exposed Children. N Engl J Med. 2011 Jul 7;365(1):21–31.

32. Gray DM, Workman LJ, Lombard CJ, Jennings T, Innes S, Grobbelaar CJ, et al. Isoniazid preventive therapy in HIV-infected children on antiretroviral therapy: a pilot study. Int J Tuberc Lung Dis. 2014 Mar;18(3):322–7.

33. Frigati LJ, Kranzer K, Cotton MF, Schaaf HS, Lombard CJ, Zar HJ. The impact of isoniazid preventive therapy and antiretroviral therapy on tuberculosis in children infected with HIV in a high tuberculosis incidence setting. Thorax. 2011 Jun 1;66(6):496–501.

34. Garcia-Prats AJ, Zimri K, Mramba Z, Schaaf HS, Hesseling AC. Children exposed to multidrug-resistant tuberculosis at a home-based day care centre: a contact investigation. Int J Tuberc Lung Dis. 2014 Nov 1;18(11):1292–8.

35. Trieu L, Proops DC, Ahuja SD. Moxifloxacin Prophylaxis against MDR TB, New York, New York, USA. Emerg Infect Dis. 2015 Mar;21(3):500–3.

36. Bamrah S, Brostrom R, Dorina F, Setik L, Song R, Kawamura LM, et al. Treatment for LTBI in contacts of MDR-TB patients, Federated States of Micronesia, 2009–2012. Int J Tuberc Lung Dis. 2014 Aug 1;18(8):912–8.

37. Schaaf HS, Gie RP, Kennedy M, Beyers N, Hesseling PB, Donald PR. Evaluation of young children in contact with adult multidrug-resistant pulmonary tuberculosis: a 30-month follow-up. Pediatrics. 2002 May;109(5):765–71.

38. Knight GM, McQuaid CF, Dodd PJ, Houben RMGJ. Global burden of latent multidrug-resistant tuberculosis: trends and estimates based on mathematical modelling. Lancet Infect Dis. 2019 Aug;19(8):903–12.

39. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach. 2nd edition. Geneva, World Health Organization; 2016. Available from: http://apps.who.int/iris/bitstream/10665/208825/1/9789241549684_eng.pdf

40. Consolidated guideline on sexual and reproductive health and rights of women living with HIV (WHO/CDS/ TB/2019.1). Geneva, World Health Organization. 2017.

41. Denholm JT, Matteelli A, Reis A. Latent tuberculous infection: ethical considerations in formulating public health policy. Int J Tuberc Lung Dis. 2015 Feb;19(2):137–40.

42. Ethics guidance for the implementation of the End TB Strategy (WHO/HTM/TB/2017.07). Geneva, World Health Organization. 2017. Available from: http://apps.who.int/iris/bitstream/10665/254820/1/9789241512114- eng.pdf

43. Resolution WHA61.17. Health of Migrants. In: Sixty-first World Health Assembly, Geneva, 19–24 May 2008, Resolutions and decisions; annexes. Geneva, World Health Organization, 2008 (WHA61/2008/REC/1):23– 25. Available from: http://apps.who.int/gb/ebwha/pdf_files/WHA62-REC1/WHA62_REC1-en.pdf

44. Kass NE. An ethics framework for public health. Am J Public Health. 2001 Nov;91(11):1776–82.

45. Getahun H, Kittikraisak W, Heilig CM, Corbett EL, Ayles H, Cain KP, et al. Development of a Standardized Screening Rule for Tuberculosis in People Living with HIV in Resource-Constrained Settings: Individual Participant Data Meta-analysis of Observational Studies. Murray M, editor. PLoS Med. 2011 Jan 18;8(1):e1000391.

46. Hamada Y, Lujan J, Schenkel K, Ford N, Getahun H. Sensitivity and specificity of WHO’s recommended foursymptom screening rule for tuberculosis in people living with HIV: a systematic review and meta-analysis. The Lancet HIV. 2018 Sep;5(9):e515–23.

47. Ahmad Khan F, Verkuijl S, Parrish A, Chikwava F, Ntumy R, El-Sadr W, et al. Performance of symptom-based tuberculosis screening among people living with HIV: not as great as hoped. AIDS. 2014 Jun;28(10):1463–72.

48. Nguyen DTM, Bang ND, Hung NQ, Beasley RP, Hwang L-Y, Graviss EA. Yield of chest radiograph in tuberculosis screening for HIV-infected persons at a district-level HIV clinic. Int J Tuberc Lung Dis. 2016 Feb;20(2):211–7.

49. Cranmer. L, Pavlinac. P, Njuguna. I, Otieno. V, Maleche-Obimbo. E, Moraa. H, et al. Performance of WHO TB symptom screen in hospitalized HIV-positive Kenyan children. 47th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease; 2016; Liverpool, United Kingdom.

50. Chest radiography in tuberculosis detection-Summary of current WHO recommendations and guidance on programmatic approaches. (WHO/HTM/TB/2016.20). Geneva, World Health Organization. 2016. Available from: https://apps.who.int/iris/bitstream/handle/10665/252424/9789241511506-eng.pdf

51. van’t Hoog A, Langendam MW, Cobelens FGJ, Sinclair D, Leeflang M, Lönnroth K. A systematic review of the sensitivity and specificity of symptom- and chest-radiography screening for active pulmonary tuberculosis in HIV-negative persons and persons with unknown HIV status. 2013. Available from: https://www.who.int/tb/Review2Accuracyofscreeningtests.pdf

52. Mulenga H, Tameris MD, Luabeya KKA, Geldenhuys H, Scriba TJ, Hussey GD, et al. The Role of Clinical Symptoms in the Diagnosis of Intrathoracic Tuberculosis in Young Children: Pediatr Infect Dis J. 2015 Nov;34(11):1157–62.

53. Kruk A, Gie RP, Schaaf HS, Marais BJ. Symptom-based screening of child tuberculosis contacts: improved feasibility in resource-limited settings. Pediatrics. 2008 Jun 1;121(6):e1646–52.

54. Triasih R, Robertson CF, Duke T, Graham SM. A Prospective Evaluation of the Symptom-Based Screening Approach to the Management of Children Who Are Contacts of Tuberculosis Cases. Clin Infect Dis. 2015 Jan 1;60(1):12–8.

55. Mandalakas AM, Hesseling AC, Gie RP, Schaaf HS, Marais BJ, Sinanovic E. Modelling the cost-effectiveness of strategies to prevent tuberculosis in child contacts in a high-burden setting. Thorax. 2013 Mar;68(3):247–55.

56. Assefa Y, Woldeyohannes S, Gelaw YA, Hamada Y, Getahun H. Screening tools to exclude active pulmonary TB in high TB burden countries: systematic review and meta-analysis. Int J Tuberc Lung Dis. 2019 Jun 1;23(6):728–34.

57. Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis. A general review. Bibl Tuberc. 1970;26:28–106.

58. Gao L, Li X, Liu J, Wang X, Lu W, Bai L, et al. Incidence of active tuberculosis in individuals with latent tuberculosis infection in rural China: follow-up results of a population-based, multicentre, prospective cohort study. Lancet Infect Dis. 2017 Oct;17(10):1053–61.

59. Rangaka MX, Wilkinson KA, Glynn JR, Ling D, Menzies D, Mwansa-Kambafwile J, et al. Predictive value of interferon-γ release assays for incident active tuberculosis: a systematic review and meta-analysis. The Lancet Infect Dis. 2012 Jan;12(1):45–55.

60. Mahomed H, Hawkridge T, Verver S, Abrahams D, Geiter L, Hatherill M, et al. The Tuberculin Skin Test versus QuantiFERON TB Gold® in Predicting Tuberculosis Disease in an Adolescent Cohort Study in South Africa. Pai M, editor. PLoS ONE. 2011 Mar 29;6(3):e17984.

61. Mathad JS, Bhosale R, Balasubramanian U, Kanade S, Mave V, Suryavanshi N, et al. Quantitative IFN-γ and IL-2 Response Associated with Latent Tuberculosis Test Discordance in HIV-infected Pregnant Women. Am J Respir Crit Care Med. 2016 Jun 15;193(12):1421–8.

62. McCarthy KM, Scott LE, Gous N, Tellie M, Venter WDF, Stevens WS, et al. High incidence of latent tuberculous infection among South African health workers: an urgent call for action. Int J Tuberc Lung Dis. 2015 Jun;19(6):647–53.

63. Sharma SK, Vashishtha R, Chauhan LS, Sreenivas V, Seth D. Comparison of TST and IGRA in Diagnosis of Latent Tuberculosis Infection in a High TB-Burden Setting. PLoS ONE. 2017 Jan 6;12(1):e0169539.

64. Dorman SE, Belknap R, Graviss EA, Reves R, Schluger N, Weinfurter P, et al. Interferon-γ Release Assays and Tuberculin Skin Testing for Diagnosis of Latent Tuberculosis Infection in Healthcare Workers in the United States. Am J Respir Crit Care Med. 2013 Dec 3;131203133239003.

65. Zwerling A, Behr MA, Verma A, Brewer TF, Menzies D, Pai M. The BCG World Atlas: A Database of Global BCG Vaccination Policies and Practices. PLoS Med. 2011 Mar 22;8(3):e1001012.

66. Zunza M, Gray DM, Young T, Cotton M, Zar HJ. Isoniazid for preventing tuberculosis in HIV-infected children. Cochrane Infectious Diseases Group, editor. Cochrane Database of Systematic Reviews. 2017 Aug 29 [cited 2019 Aug 28]; Available from: http://doi.wiley.com/10.1002/14651858.CD006418.pub3

67. Smieja M, Marchetti C, Cook D, Smaill FM. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Infectious Diseases Group, editor. Cochrane Database of Systematic Reviews. 1999 Jan 25 [cited 2019 Aug 28]; Available from: http://doi.wiley.com/10.1002/14651858.CD001363

68. Zenner D, Beer N, Harris RJ, Lipman MC, Stagg HR, van der Werf MJ. Treatment of Latent Tuberculosis Infection: An Updated Network Meta-analysis. Ann Intern Med. 2017 Aug 15;167(4):248.

69. Comstock GW. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis. 1999 Oct;3(10):847–50.

70. Den Boon S, Matteelli A, Ford N, Getahun H. Continuous isoniazid for the treatment of latent tuberculosis infection in people living with HIV: AIDS. 2016 Mar;30(5):797–801.

71. Stagg HR, Zenner D, Harris RJ, Muñoz L, Lipman MC, Abubakar I. Treatment of Latent Tuberculosis Infection: A Network Meta-analysis. Ann Intern Med. 2014 Sep 16;161(6):419.

72. Galli L, Lancella L, Tersigni C, Venturini E, Chiappini E, Bergamini B, et al. Pediatric Tuberculosis in Italian Children: Epidemiological and Clinical Data from the Italian Register of Pediatric Tuberculosis. IJMS. 2016 Jun 17;17(6):960.

73. Spyridis NP, Spyridis PG, Gelesme A, Sypsa V, Valianatou M, Metsou F, et al. The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. Clin Infect Dis. 2007 Sep 15;45(6):715–22.

74. van Zyl S, Marais BJ, Hesseling AC, Gie RP, Beyers N, Schaaf HS. Adherence to anti-tuberculosis chemoprophylaxis and treatment in children. Int J Tuberc Lung Dis. 2006 Jan;10(1):13–8.

75. Menzies D, Adjobimey M, Ruslami R, Trajman A, Sow O, Kim H, et al. Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults. N Engl J Med. 2018 Aug 2;379(5):440–53.

76. Diallo T, Adjobimey M, Ruslami R, Trajman A, Sow O, Obeng Baah J, et al. Safety and Side Effects of Rifampin versus Isoniazid in Children. N Engl J Med. 2018 Aug 2;379(5):454–63.

77. Menzies D, Long R, Trajman A, Dion M-J, Yang J, Al Jahdali H, et al. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Ann Intern Med. 2008 Nov 18;149(10):689–97.

78. Menzies D, Dion M-J, Rabinovitch B, Mannix S, Brassard P, Schwartzman K. Treatment Completion and Costs of a Randomized Trial of Rifampin for 4 Months versus Isoniazid for 9 Months. Am J Respir Crit Care Med. 2004 Aug 15;170(4):445–9.

79. Swindells S, Ramchandani R, Gupta A, Benson CA, Leon-Cruz J, Mwelase N, et al. One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. N Engl J Med. 2019 Mar 14;380(11):1001–11.

80. Martinson NA, Barnes GL, Moulton LH, Msandiwa R, Hausler H, Ram M, et al. New Regimens to Prevent Tuberculosis in Adults with HIV Infection. N Engl J Med. 2011 Jul 7;365(1):11–20.

81. Sterling TR, Scott NA, Miro JM, Calvet G, La Rosa A, Infante R, et al. Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons: AIDS. 2016 Jun;30(10):1607–15.

82. Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, et al. Three Months of Rifapentine and Isoniazid for Latent Tuberculosis Infection. N Engl J Med. 2011 Dec 8;365(23):2155–66.

83. Villarino ME, Scott NA, Weis SE, Weiner M, Conde MB, Jones B, et al. Treatment for Preventing Tuberculosis in Children and Adolescents: A Randomized Clinical Trial of a 3-Month, 12-Dose Regimen of a Combination of Rifapentine and Isoniazid. JAMA Pediatr. 2015 Mar 1;169(3):247.

84. Moro RN, Scott NA, Vernon A, Tepper NK, Goldberg SV, Schwartzman K, et al. Exposure to Latent Tuberculosis Treatment during Pregnancy. The PREVENT TB and the iAdhere Trials. Annals ATS. 2018 May;15(5):570–80.

85. Belknap R, Holland D, Feng P-J, Millet J-P, Caylà JA, Martinson NA, et al. Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection: A Randomized Trial. Ann Intern Med. 2017 Nov 21;167(10):689.

86. Dolutegravir (DTG) and the fixed dose combination (FDC) of tenofovir/lamivudine/dolutegravir (TLD). Geneva, World Health Organization; 2018. Available from: https://www.who.int/hiv/pub/arv/DTG-TLD-arv_briefing_2018.pdf

87. Podany AT, Bao Y, Swindells S, Chaisson RE, Andersen JW, Mwelase T, et al. Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention. Clin Infect Dis. 2015 Oct 15;61(8):1322–7.

88. Weiner M, Egelund EF, Engle M, Kiser M, Prihoda TJ, Gelfond JAL, et al. Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers. J Antimicrob Chemother. 2014 Apr 1;69(4):1079–85.

89. Brooks KM, George JM, Pau AK, Rupert A, Mehaffy C, De P, et al. Cytokine-Mediated Systemic Adverse Drug Reactions in a Drug–Drug Interaction Study of Dolutegravir With Once-Weekly Isoniazid and Rifapentine. Clin Infect Dis. 2018 Jul 2;67(2):193–201.

90. Dooley KE, Churchyard G, Savic RM, Gupte A, Marzinke MA, Zhang N, et al. Safety & PK of weekly rifapentine/isoniazid (3HP) in adults with HIV on dolutegravir. In: TB: FROM CONTACT TO CURE AND BEYOND (Abstract Number: 80). Seattle, Washington, USA; 2019 [cited 2019 Apr 25]. Available from: http://www.croiconference.org/sessions/safety-pk-weekly-rifapentineisoniazid-3hp-adults-hiv-dolutegravir

91. Gupta A, Montepiedra G, Aaron L, Theron G, McCarthy K, Onyango-Makumbi C et al. Randomized trial of safety of isoniazid preventive therapy during or after pregnancy. In: CRITICAL ISSUES IN WOMEN’S HEALTH AND EARLY TREATMENT OF PEDIATRIC HIV INFECTION (Abstract Number: 142LB). Boston, Massachusetts, USA; 2018 [cited 2019 Apr 25]. Available from: http://www.croiconference.org/sessions/randomized-trial-safety-isoniazid-preventive-therapy-during-or-after-pregnancy

92. Gupta A, Montepiedra G, Aaron L, Theron G, McCarthy K, Bradford S, et al. Isoniazid Preventive Therapy in HIV-Infected Pregnant and Postpartum Women. N Engl J Med. 2019 Oct 3;381(14):1333–46.

93. Taylor AW, Mosimaneotsile B, Mathebula U, Mathoma A, Moathlodi R, Theebetsile I, et al. Pregnancy Outcomes in HIV-Infected Women Receiving Long-Term Isoniazid Prophylaxis for Tuberculosis and Antiretroviral Therapy. Infect Dis Obstet Gynecol. 2013;2013:1–5.

94. Salazar-Austin N, Cohn S, Lala S, Waja Z, Dooley KE, Hoffmann CJ, et al. Isoniazid Preventive Therapy and Pregnancy Outcomes In HIV-Infected Women in the Tshepiso Cohort. Clin Infect Dis. 2019 Oct 21;ciz1024.

95. Kalk EK, Heekes A, Mehta U, de Waal R, Jacob N, Cohen K, et al. Programmatic review of safety and effectiveness of isoniazid preventive therapy in HIV-infected pregnant women on ART in routine care. Reproductive Toxicology. 2018 Sep;80:155.

96. Guidelines for the treatment of drug-susceptible tuberculosis and patient care, 2017 update. (WHO/HTM/TB/2017.05). Geneva, World Health Organization. 2017. Available from: http://apps.who.int/iris/bitstream/10665/255052/1/9789241550000-eng.pdf

97. Takizawa T, Hashimoto K, Minami T, Yamashita S, Owen K. The comparative arthropathy of fluoroquinolones in dogs. Hum Exp Toxicol. 1999 Jun;18(6):392–9.

98. Hampel B, Hullmann R, Schmidt H. Ciprofloxacin in pediatrics: worldwide clinical experience based on compassionate use--safety report. Pediatr Infect Dis J. 1997 Jan;16(1):127–9; discussion 160–162.

99. Warren RW. Rheumatologic aspects of pediatric cystic fibrosis patients treated with fluoroquinolones. Pediatr Infect Dis J. 1997 Jan;16(1):118–22; discussion 123–126.

100. Acar S, Keskin-Arslan E, Erol-Coskun H, Kaya-Temiz T, Kaplan YC. Pregnancy outcomes following quinolone and fluoroquinolone exposure during pregnancy: A systematic review and meta-analysis. Reproductive Toxicology. 2019 Apr;85:65–74.

101. Safety announcement -> FDA reinforces safety information about serious low blood sugar levels and mental health side effects with fluoroquinolone antibiotics; requires label changes. 2018. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/ fda-reinforces-safety-information-about-serious-low-blood-sugar-levels-and-mental-health-side

102. Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics. European Medicines Agency; 2019. Available from: https://www.ema.europa. eu/en/documents/referral/quinolone-fluoroquinolone-article-31-referral-disabling-potentially-permanentside- effects-lead_en.pdf

103. WHO | LTBI care: a mobile app to support programmatic management of LTBI. WHO. 2017. Available from: https://www.who.int/tb/areas-of-work/preventive-care/ltbi/ltbi_app/en/

104. Getahun H, Matteelli A, Abubakar I, Hauer B, Pontali E, Migliori GB. Advancing global programmatic management of latent tuberculosis infection for at risk populations. Eur Respir J. 2016 May;47(5):1327–30.

105. Sotgiu G, Matteelli A, Getahun H, Girardi E, Sañé Schepisi M, Centis R, et al. Monitoring toxicity in individuals receiving treatment for latent tuberculosis infection: a systematic review versus expert opinion. Eur Respir J. 2015 Apr;45(4):1170–3.

106. Balcells ME, Thomas SL, Godfrey-Faussett P, Grant AD. Isoniazid Preventive Therapy and Risk for Resistant Tuberculosis. Emerg Infect Dis. 2006 May;12(5):744–51.

107. Den Boon S, Matteelli A, Getahun H. Rifampicin resistance after treatment for latent tuberculous infection: a systematic review and meta-analysis. Int J Tuberc Lung Dis. 2016;20(8):1065–71.

108. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. (WHO/HTM/TB/2014.11). Geneva, World Health Organization; 2015. Available from: http://apps.who.int/iris/bitstream/10665/130918/1/9789241548809_eng.pdf

109. Active tuberculosis drug-safety monitoring and management (aDSM). Framework for implementation (WHO/HTM/TB/2015.28). Geneva, World Health Organization; 2015. Available from: http://apps.who.int/ iris/bitstream/10665/204465/1/WHO_HTM_TB_2015.28_eng.pdf

Book navigation